# Cardinal Health Inc: Form 10-Q for the period ended Dec 31, 2025

- Company: [Cardinal Health Inc](/companies/cah.md) (CIK 721371)
- Form: 10-Q
- Filed: 2026-02-05
- Accepted by EDGAR: Feb 5, 2026, 08:47 ET
- Period: 2025-12-31
- Accession: 0000721371-26-000006
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/721371/000072137126000006/cah-20251231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/721371/000072137126000006/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-10-01 to 2025-12-31 | $65.63bn | us-gaap:Revenues |
| Revenue | 6 months, 2025-07-01 to 2025-12-31 | $129.64bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2025-10-01 to 2025-12-31 | $63.23bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2025-07-01 to 2025-12-31 | $124.92bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2025-10-01 to 2025-12-31 | $2.40bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2025-07-01 to 2025-12-31 | $4.72bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2025-10-01 to 2025-12-31 | $1.50bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2025-07-01 to 2025-12-31 | $2.96bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-10-01 to 2025-12-31 | $707.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2025-07-01 to 2025-12-31 | $1.38bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-10-01 to 2025-12-31 | $88.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2025-07-01 to 2025-12-31 | $168.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2025-10-01 to 2025-12-31 | $159.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2025-07-01 to 2025-12-31 | $303.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-10-01 to 2025-12-31 | $467.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2025-07-01 to 2025-12-31 | $917.0m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2025-10-01 to 2025-12-31 | 237,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2025-07-01 to 2025-12-31 | 238,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2025-07-01 to 2025-12-31 | $1.66bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2025-07-01 to 2025-12-31 | $239.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2025-07-01 to 2025-12-31 | $251.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2025-07-01 to 2025-12-31 | $758.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2025-12-31 | $2.78bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-12-31 | $39.23bn | us-gaap:AssetsCurrent |
| Total assets | at 2025-12-31 | $58.08bn | us-gaap:Assets |
| Current liabilities | at 2025-12-31 | $43.31bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2025-12-31 | −$2.88bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/721371/000072137126000006/cah-20251231.htm

Filed Feb 5, 2026.
Source: SEC EDGAR, the filing index for accession 0000721371-26-000006. Last ingested by Listed: Nov 5, 2026, 12:30 ET. No prices; not investment advice.